This article was originally published in The Gray Sheet
Laboratory Corporation of America plans July 20 commercial release of Antivirogram and VircoGen diagnostic testing procedures to evaluate resistance of HIV to antiretroviral drugs via its collaborative partnership with Virco. Antivirogram assesses viral sensitivity to anti-HIV drugs by measuring the ability of the virus to grow in the presence of each drug. The VircoGen genotypic test identifies genetic mutations that can signify drug resistance
You may also be interested in...
Gilead Sciences will leverage its 60-rep U.S. sales force under a collaborative promotional and educational effort with Virco to increase awareness among physicians treating patients with HIV of Virco's phenotypic and genotypic HIV resistance monitoring assays, the firms announced March 7.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker